Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Non Operating Income (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Non Operating Income for 4 consecutive years, with $881000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 2.44% to $881000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 17.41% year-over-year, with the annual reading at $6.0 million for FY2025, 17.41% down from the prior year.
  • Non Operating Income for Q4 2025 was $881000.0 at TScan Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Non Operating Income was $2.7 million in Q3 2024, with the low at -$74000.0 in Q4 2022.
  • Average Non Operating Income over 4 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Non Operating Income soared 2471.43% in 2023, then tumbled 50.93% in 2025.
  • Over 4 years, Non Operating Income stood at -$74000.0 in 2022, then soared by 2456.76% to $1.7 million in 2023, then plummeted by 48.22% to $903000.0 in 2024, then fell by 2.44% to $881000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $881000.0, $1.3 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.